|
|
Metabolomics
As part of its integrated platform, BG Medicine has developed advanced metabolomics capabilities that measure, identify and characterize a wide breadth of endogenous small molecules, or metabolites, which are found in bodily fluids and in tissues. These dynamic molecules are fundamental to all biological processes, and as such form a key component of biomarker discovery and validation programs. We deploy a portfolio of specialized workflows to measure these molecules from extremely small volumes of starting sample. In performing metabolomics measurements over many years, we have established extensive internal proprietary databases of identified and characterized metabolites found in bodily fluids and tissues, across many diseases and treatments, yielding exceptionally efficient and productive workflows.
Molecular Metabolomics Platforms
Lipid LC/MS lysophospholipids, phospholipids, cholesterol esters, di- and tri-acylglycerols, sphingomyelins, ceramides, related molecules Requires 5-10 μL plasma
Polar LC/MS GC/MS Amino acids, sugars, alcohols, aldehydes and cyclohexanols, amines, aromatic compounds, organic acids, phospho-organic acids, sugar acids, sugar amines, sugar phosphates Requires 35 μL plasma
Free Fatty Acid LC/MS - C8 to C26 free fatty acids with 0 to 6 double bonds
- Requires 10 μL plasma
NMR - Amino acids, amino acid metabolites, organic acids, sugars, related molecules
- Requires 250-400 μL plasma.
Data Quality
Using regulated standard operating procedures, a sophisticated and dedicated corporate QA/QC function, and proprietary, optimized data processing and normalization processes, BG Medicine achieves extremely low analytical variances across all of its metabolomics platforms. This level of stringency is fundamental to the ability to detect subtle biological changes at the molecular level and to evaluate the appropriateness of biological molecules as biomarkers.
|
